Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women

被引:90
作者
Mayer, KH
Karim, SA
Kelly, C
Maslankowski, L
Rees, H
Profy, AT
Day, J
Welch, J
Rosenbergh, Z
机构
[1] Brown Univ, Miriam Hosp, Div Infect Dis, Providence, RI 02906 USA
[2] Fenway Community Hlth, Boston, MA USA
[3] Univ KwaZulu Natal, ZA-4001 Durban, South Africa
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[6] WITS Med Sch, Johannesburg, South Africa
[7] Chris Hani Baragwanath Hosp, Johannesburg, South Africa
[8] MRC, Durban, South Africa
[9] Interneuron Pharmaceut Inc, Lexington, MA USA
[10] ABT Associates Inc, Cambridge, MA 02138 USA
[11] Family Hlth Int, Res Triangle Pk, NC 27709 USA
关键词
microbicide; vaginal gel; HIV; phase I trial;
D O I
10.1097/00002030-200302140-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate once or twice daily vaginal exposure to 2 and 4% PRO 2000 Gel, a naphthalene sulfonate polymer microbicide, in sexually active HIV-uninfected women to determine the highest tolerated frequency and concentration combination, and to assess this in sexually abstinent HIV-infected women. Methods: Sixty three women from Providence, Philadelphia, Durban and Johannesburg were enrolled after being screened to exclude pre-existing illnesses and were instructed to use the product once or twice daily for 14 intermenstrual days. They underwent colposcopy prior to product use and after 14 days of product use, with a pelvic examination at day 7. Results: The product was well tolerated with no serious adverse events, even though 73% of the participants had at least one adverse experience: 82% of these were classified as mild, and over 90% of the findings and symptoms were localized to the genital tract. Women who used the 4% gel twice daily tended to have more adverse events than all the other groups. Three participants did not complete the study; one because of Herpes simplex virus cervicitis, the second because of epithelial disruption, and the third because she became be pregnant. The remaining participants adhered to the study protocol and indicated that they would use the product if it were shown to be effective. Conclusions: PRO 2000 Gel was safe and well tolerated in sexually active HIV-uninfected and sexually abstinent HIV-infected women, enabling the product to be considered for evaluation in efficacy trials. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:321 / 329
页数:9
相关论文
共 32 条
[1]  
Anderson DJ, 1998, AIDS RES HUM RETROV, V14, pS43
[2]   The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model [J].
Bourne, N ;
Bernstein, DI ;
Ireland, J ;
Sonderfan, AJ ;
Profy, AT ;
Stanberry, LR .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :203-205
[3]  
Cohen J, 2001, SHOTS DARK WAYWARD S
[4]  
CONNOR TJ, 1995, INT J STD AIDS, V6, P267
[5]  
ELIAS C, 1996, AIDS WORLD I GLOBAL, P196
[6]   CHALLENGES FOR THE DEVELOPMENT OF FEMALE-CONTROLLED VAGINAL MICROBICIDES [J].
ELIAS, CJ ;
HEISE, LL .
AIDS, 1994, 8 (01) :1-9
[7]   Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides [J].
Greenhead, P ;
Hayes, P ;
Watts, PS ;
Laing, KG ;
Griffin, GE ;
Shattock, RJ .
JOURNAL OF VIROLOGY, 2000, 74 (12) :5577-5586
[8]  
HILL R, 2000, J PHARM MED, V14, P271
[9]  
KEMPF C, 1991, J ACQ IMMUN DEF SYND, V4, P828
[10]   EFFICACY OF NONOXYNOL-9 CONTRACEPTIVE SPONGE USE IN PREVENTING HETEROSEXUAL ACQUISITION OF HIV IN NAIROBI PROSTITUTES [J].
KREISS, J ;
NGUGI, E ;
HOLMES, K ;
NDINYAACHOLA, J ;
WAIYAKI, P ;
ROBERTS, PL ;
RUMINJO, I ;
SAJABI, R ;
KIMATA, J ;
FLEMING, TR ;
ANZALA, A ;
HOLTON, D ;
PLUMMER, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (04) :477-482